Fans for the Cure

Contact Subscribe Donate
Teaming up against prostate cancer
  • Prostate Cancer
    • Signs & Symptoms
    • Risk Factors
    • Screening & Diagnosis
    • Online Resources
  • What We Do
    • Prostate Cancer Awareness and Education
    • PSA Screenings and Raising Testing Awareness
    • Prostate Health Medical Referrals
  • About Us
    • Partners
    • Medical Advisory Board
    • Legends of Life Board
    • Board of Directors
    • Ed Randall
  • Our Events
    • All-Star Celebration Dinner 2019
    • Baseball Road Trip: 2018
  • News + Blog
    • Medical News and Blog
    • My Stories
    • FANS MVP
  • Get Involved
    • Donate
    • Subscribe
    • Buy with AmazonSmile
    • Prostate Cancer Survivors: Share Your Story
    • Voices from the Community: Share Your Story
    • Volunteer
  • Ask a Question About Prostate Cancer

Molecular Profiling of Low-Grade Prostate Cancers to Improve Active Surveillance Effectiveness

May 24, 2017 by Fans for the Cure

Doctors and researchers at Cleveland Clinic have published a study where they noted that approximately 20 percent of 3+3=6 prostate cancers harbor genomic alterations associated with an increased risk of metastatic disease. Molecular profiling may prove a valuable tool in enabling physicians and medical professionals to more accurately and reliably determine if active surveillance of prostate cancer is the best solution for a specific patient.

According to Dr. Eric Klein, Chair of Cleveland Clinic Glickman Urological & Kidney Institute, “[The] study shows that men with prostate cancer stand to benefit from molecular profiling at the time of diagnosis, in conjunction with Gleason scoring and use of other prognostic tools, because it helps both to improve patient selection for active surveillance and inform treatment decisions for those who require immediate intervention.”

Utilizing the Decipher® test and blinded pathology assessments, this Cleveland Clinic study reveals that one-in-five prostate cancers with the lowest possible Gleason score (3+3=6) have molecular alterations consistent with aggressive disease and the potential to metastasize.

Connecting Molecular Profiling to Active Surveillance

Given the findings, Dr. Klein stated that with active surveillance representing the best option for many men with low-grade prostate cancer, the use of molecular profiling – to help identify which cancers might metastasize – will increase the effectiveness with which doctors select patients for active surveillance (versus a more immediate, aggressive form of treatment for prostate cancer.)

***
Read the original article online: https://consultqd.clevelandclinic.org/2017/05/low-grade-prostate-cancers-show-molecular-features-aggressive-cancer/

Filed Under: Blog

Recent News + Blog Posts

  • Fans for the Cure Partners with the Metastatic Prostate Cancer Project to Accelerate Prostate Cancer Research February 12, 2019
  • SAVE THE DATE: All-Star Celebration Dinner, June 11, 2019 February 12, 2019
  • AUCTION ALERT: ONLY A FEW DAYS LEFT TO BID ON INCREDIBLE BASEBALL EXPERIENCES February 8, 2019
  • A Sincere Thank You to All of Our Generous Supporters in 2018 January 2, 2019

Ask Us a Question »

Shop AmazonSmile + Support Us

Fans for the Cure Logo

Fans for the Cure

Fans for the Cure is a nonprofit charity that is recognized as tax-exempt by the IRS under Section 501(c)(3). Your gift to FFTC may qualify as a charitable deduction for federal income tax purposes. Please consult with your tax advisers or with the IRS to determine whether a specific contribution is deductible.

On This Site

  • Home
  • Prostate Cancer
  • What We Do
  • About Us
  • News + Blog
  • Get Involved
  • Contact
  • Ask Us a Question
  • Brand Assets
  • Accessibility
  • Privacy Policy
  • Sitemap

Shop AmazonSmile + Support Us

Contact Us

Phone: 212-687-4164
Email: edrandall@fans4thecure.org

Connect With Us

  • Facebook
  • Flickr
  • Google+
  • Twitter
  • YouTube

© Copyright 2015 - 2019 Fans for the Cure, all rights reserved. A web creation by LBDesign.